Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca and Max Planck Institute announce research agreement to create satellite chemistry unit for cardiovascular and metabolic diseases

08 July 2014

AstraZeneca today announced an agreement with the Max Planck Institute
of Molecular Physiology (MPI), Germany, to establish a `satellite
unit' in cardiovascular and metabolic disease (CVMD), linked to
AstraZeneca's CVMD Innovative Medicines unit (iMed) in Mölndal,
Sweden, to study new modalities chemistry.

The new collaboration will see AstraZeneca scientists working
side-by-side with researchers from the Max Planck Institute of
Molecular Physiology, in the Department of Chemical Biology, led by
Professor Herbert Waldmann. The satellite unit will focus on novel
chemistry and chemical biology in areas of new modality chemistry
such as stabilised peptides, macrocycles and conjugation chemistry.

Marcus Schindler, Vice President and Head of CVMD iMed, AstraZeneca,
said: "I'm very pleased to collaborate with an internationally
recognised academic institution such as the Max Planck Institute of
Molecular Physiology. Based on our excellent ongoing collaboration
with Professor Waldmann's group and the interdisciplinary Chemical
Genomics Centre, we are confident that this innovative new
partnership will result in exciting scientific findings, addressing
chemical challenges primarily in the field of new modalities."

Professor Herbert Waldmann, Director of the Department of Chemical
Biology, MPI Dortmund, said: "This novel concept for a strategic
alliance between an innovation-driven pharmaceutical company and a
leading biomedical institute like the Max Planck Institute of
Molecular Physiology promises to break new ground for drug discovery.
AstraZeneca is one of the leading global pharmaceutical companies and
we are pleased and very much looking forward to the collaboration.
Uniting our strengths will give rise to novel innovative approaches
to drug discovery."

Cardiovascular and metabolic diseases represent one of AstraZeneca's
three core therapy areas, with the aim of developing innovative
treatments that address the underlying biology to stop, reverse or
cure diseases with high unmet medical need. The collaboration with
the Max Planck Institute will support identification of new targets
in the company's three areas of research focus in CVMD: cardiac
regeneration, islet health (diabetes) and diabetic nephropathy.

In March 2013
AstraZeneca initiated a similar collaboration with the Swedish
medical university Karolinska Institutet that created an Integrated
Translational Research Centre (ICMC) for cardiovascular and metabolic
disease and regenerative medicine located at Karolinska Institutet's
site in Stockholm, Sweden. The ICMC conducts preclinical and clinical
studies aimed at advancing the understanding of cardiovascular and
metabolic disease pathophysiology and assessing new drug targets for
AstraZeneca's two biotech units, the iMed and MedImmune.


Notes to editors

About Max Planck Institute of Molecular Physiology

Following its scientific mission, "From molecule to man.", the Max
Planck Institute of Molecular Physiology, Dortmund conducts basic
biomedical research. At the interface between structural biology,
molecular cell biology and chemical biology, the Institute's
scientists pursue interdisciplinary research leading to a unique
liaison between chemistry and biology. Identification and synthesis
of near-natural active substances enables accurate modulation of
intracellular processes to unravel and understand the molecular
causes of diseases. For more information, please visit:

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:


Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Ayesha Bharmal +44 20 7604 8034 (UK/Global)


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.